0000950170-24-038106.txt : 20240328
0000950170-24-038106.hdr.sgml : 20240328
20240328163330
ACCESSION NUMBER: 0000950170-24-038106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240326
FILED AS OF DATE: 20240328
DATE AS OF CHANGE: 20240328
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sullivan Lara
CENTRAL INDEX KEY: 0001769457
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40881
FILM NUMBER: 24799683
MAIL ADDRESS:
STREET 1: C/O REXAHN PHARMACEUTICALS, INC.
STREET 2: 15245 SHADY GROVE ROAD, SUITE 455
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pyxis Oncology, Inc.
CENTRAL INDEX KEY: 0001782223
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831160910
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 HARRISON AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02118
BUSINESS PHONE: (617) 221-9059
MAIL ADDRESS:
STREET 1: 321 HARRISON AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02118
4
1
ownership.xml
4
X0508
4
2024-03-26
false
0001782223
Pyxis Oncology, Inc.
PYXS
0001769457
Sullivan Lara
C/O PYXIS ONCOLOGY, INC.
321 HARRISON AVENUE, 11TH FL. SUITE 1
BOSTON
MA
02118
true
true
false
false
Chief Executive Officer
false
Stock Option (Right to Buy)
3.83
2024-03-26
4
A
false
1071242
3.83
A
2034-03-26
Common Stock
1071242
1071242
D
The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 26, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
/s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan
2024-03-28